According to the National Cancer Institute, Adrenocortical Carcinoma (ACC) is rare cancer that originates in the outer layer of the adrenal gland. ACC is also called cancer of the adrenal cortex. A tumor of the adrenal cortex may be functioning (produces surplus hormones than usual) or nonfunctioning (does not produce surplus hormones than usual). Most adrenocortical tumors are functioning.
The hormones made by functioning tumors may cause sure signs or symptoms of the disease; the common symptoms caused by ACC include a lump in the abdomen, pain in the abdomen or back, and feeling of fullness in the abdomen.
A non functioning adrenocortical tumor may not cause signs or symptoms in the early stages. The excessive hormones produced by a functioning tumor include cortisol, aldosterone, testosterone, and estrogen. These excessive hormones cause specific symptoms.
The Adrenocortical Carcinoma market report covers emerging drugs, current treatment practices, Adrenocortical Carcinoma market share of the individual therapies, current and forecasted Adrenocortical Carcinoma Market Size from 2017 to 2030 segmented by seven major markets.
The report also provides detailed current Adrenocortical Carcinoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Adrenocortical Carcinoma Market Key Facts
According to the study by Johanssen et al. titled “Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany,” the incidence of ACC is one per million population, and females are more frequently affected than males, with a female:male ratio of 1.5 : 1.
ACC is a rare malignancy with poor prognosis. It occurs at any age, with two peak incidences: the first in the first decade and the second between 40‒50 years.
According to the study by Wang et al. titled “Prognostic Factors of Adrenocortical Carcinoma: An Analysis of the Surveillance Epidemiology and End Results (SEER) Database,” ACC was predominant in females (60.6%) than in males (39.4%).
The study conducted by Sharma et al. titled “The Characteristics and Trends in Adrenocortical Carcinoma: A United States Population-Based Study,” shows that the median age at diagnosis was 55 years.
Visit For Sample Pages:
Key Benefits of Adrenocortical Carcinoma Market Report
Adrenocortical Carcinoma market report provides an in-depth analysis of Adrenocortical Carcinoma Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Adrenocortical Carcinoma market report will help in developing business strategies by understanding the Adrenocortical Carcinoma Market trends & developments, key players and future market competition that will shape and drive the Adrenocortical Carcinoma market in the upcoming years.
The Adrenocortical Carcinoma market report covers Adrenocortical Carcinoma current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Adrenocortical Carcinoma market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Adrenocortical Carcinoma market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Adrenocortical Carcinoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Adrenocortical Carcinoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
The Adrenocortical Carcinoma epidemiology section covers insights about historical and current Adrenocortical Carcinoma patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The Adrenocortical Carcinoma Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adrenocortical Carcinoma market or expected to get launched in the market during the study period. The analysis covers Adrenocortical Carcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The current clinical pipeline of Adrenocortical Carcinoma is weak. Some of the emerging drugs in the Adrenocortical Carcinoma (ACC) Market include EO2401, Steroidogenic Factor 1 (SF-1) and others.
The key players that are working toward the development of therapies for ACC are Exelixis, Enterome, Orphagen Pharmaceuticals, and others.
Table of Content
1. Key Insights
2. Executive Summary
3. Adrenocortical Carcinoma Competitive Intelligence Analysis
4. Adrenocortical Carcinoma Market Overview at a Glance
5. Adrenocortical Carcinoma Disease Background and Overview
6. Adrenocortical Carcinoma Patient Journey
7. Adrenocortical Carcinoma Epidemiology and Patient Population
8. Adrenocortical Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Adrenocortical Carcinoma Unmet Needs
10. Key Endpoints of Adrenocortical Carcinoma Treatment
11. Adrenocortical Carcinoma Marketed Products
12. Adrenocortical Carcinoma Emerging Therapies
13. Adrenocortical Carcinoma Seven Major Market Analysis
14. Attribute Analysis
15. Adrenocortical Carcinoma Market Outlook (7 major markets)
16. Adrenocortical Carcinoma Access and Reimbursement Overview
17. KOL Views on the Adrenocortical Carcinoma Market.
18. Adrenocortical Carcinoma Market Drivers
19. Adrenocortical Carcinoma Market Barriers
21. DelveInsight Capabilities
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Adrenocortical Carcinoma Epidemiology Forecast to 2030
DelveInsight’s Adrenocortical Carcinoma Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Adrenocortical Carcinoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Adrenocortical Carcinoma Pipeline Insights, 2020
Adrenocortical Carcinoma Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Adrenocortical Carcinoma market.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States